Retro Shmup ‘Earthion' Will Be Finally Released Later This Year
'Earthion' was developed natively on the Sega Genesis. Ancient Corporation
Earthion is one of the best-looking shmups of recent years, and it is finally coming out this year; it's even getting a Genesis cartridge release.
Developed natively on a Sega Genesis (or MegaDrive for the more cultured of you), Earthion looks and sounds astonishing.
The latter part should come as no surprise, as the game's music is being composed by the legendary Yuzo Koshiro.
If you remember, I interviewed Koshiro back when Actraiser Renaissance was released. The remastered music for that was also entirely excellent.
Ever since, I've been following Koshiro on Twitter/X to see what he's been up to, and Earthion caught my attention a good while back.
'Earthion' looks to be a thoroughly classic shmup. Ancient Corporation
Looking like the ultimate classic retro shmup, the fact that it was natively developed on the Genesis is rather bonkers but actually makes a lot of sense.
Instead of trying to ape a classic 16-bit console on modern hardware, why not develop the game properly on the original console?
The final game (shown below) looks astonishing and even gives the likes of Ex-Ranza a run for its money.
Released later this year, you can already wishlist the game on Steam, but it will also be released on PlayStation 5, PlayStation 4, Xbox Series X|S, and Nintendo Switch.
The really nice touch is that Earthion will also be released on Genesis via cartridge, which I wholeheartedly approve of.
So if you're into classic shmups, Earthion looks like it will definitely scratch that gaming itch once it's released later this year.
Follow me on X , Facebook and YouTube . I also manage Mecha Damashii and am currently featured in the Giant Robots exhibition currently touring Japan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
South Korea's Retail Investors Push for Change Among Corporate Laggards
South Korea's small investors are trying to shake up the country's creaky corporate landscape. Gathering on social media platform like KakaoTalk and dedicated shareholder apps, their aim is to give a jolt to Korea's famously undervalued stock market. Bloomberg TV's Shery Ahn explains. (Source: Bloomberg)
Yahoo
an hour ago
- Yahoo
China's AI lab unveils RoboBrain 2.0 model to accelerate humanoid robot development
In a move that will further assert China's bid to scale robotics industry, the Beijing Academy of Artificial Intelligence (BAAI)—a not for profit research laboratory—unveiled last week a series of new open-source artificial intelligence (AI) models, dubbed RoboBrain 2.0, that will function as the 'brain' of robots. According to BAAI head Wang Zhongyuan, the use of powerful AI models in China's booming robotics market could accelerate the development and adoption of humanoids, as the sector works to overcome key challenges such as limited model capabilities and a lack of high-quality training data. Wang further explained that BAAI is actively seeking collaboration across the embodied intelligence industry, emphasizing the importance of joint efforts to accelerate progress. He noted that the institute is working with more than 20 leading companies in the sector and is looking to expand its network of partners to drive continued growth. Unveiled as part of China's broader push to advance intelligent machines, RoboBrain 2.0 was described by Wang as the world's most powerful open-source AI model designed to enhance a wide range of robots, including humanoids. Its debut positions BAAI as a potential key player in the evolving sector, the South China Morning Post reported. Furthermore, RoboBrain 2.0 introduces major improvements in spatial intelligence and task planning, delivering a 17% boost in speed and a 74% increase in accuracy compared to the previous version launched just three months earlier. With enhanced spatial intelligence, robots can now perceive distances from surrounding objects more precisely, while advanced task planning enables them to autonomously deconstruct complex activities into manageable steps, significantly improving overall performance. The RoboBrain model is part of the Wujie series, which also includes RoboOS 2.0—a cloud platform for deploying robotics AI models—and Emu3, a multimodal system capable of interpreting and generating text, images, and video. BAAI is one of China's early developers of open-source large language models, the technology behind generative AI chatbots. Several former employees have used their experience at BAAI to start their own AI companies, helping to grow the AI startup community in China. China's push to lead in robotics AI involves multiple players, with BAAI joined by the Beijing Humanoid Robot Innovation Centre, which earlier this year launched Hui Si Kai Wu—a general-purpose embodied AI platform. The center is also known for developing the Tien Kung humanoid robot, which made headlines after completing a half-marathon in Beijing in April. The Chinese institution aims to have its platform become the "Android of humanoid robots," serving as a standard operating system much like Google's Android does in the smartphone industry. Moreover, this year's edition of the BAAI Conference attracted over 100 AI researchers from around the world and more than 200 industry experts, including leaders from major Chinese tech companies such as Baidu, Huawei Technologies, and Tencent Holdings. Additionally, the Chinese academy also announced a strategic partnership with the Hong Kong Investment Corporation to collaborate on talent development, technology advancement, and capital investment aimed at fostering innovation and entrepreneurship in the country's AI sector.
